The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
暂无分享,去创建一个
Ping Zhang | Frauke Becker | Mark Lamotte | Alastair Gray | Seamus Kent | Talitha Feenstra | An Tran-Duy | Iryna Schlackow | Michelle Tew | Wen Ye | Shi Lizheng | William Herman | Phil McEwan | Wendelin Schramm | Jose Leal | Michael Willis | Andrew J Palmer | Philip Clarke | A. Gray | W. Herman | Ping Zhang | A. Palmer | P. McEwan | J. Leal | M. Willis | W. Schramm | T. Feenstra | M. Lamotte | S. Kent | I. Schlackow | P. Clarke | M. Tew | Wen Ye | A. Tran‐Duy | F. Becker | Shi Lizheng | P. Mcewan | Lizheng Shi
[1] William Herrington,et al. A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease , 2017, Heart.
[2] Ping Zhang,et al. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[3] Douglas K Owens,et al. Future Directions for Cost-effectiveness Analyses in Health and Medicine , 2018, Medical decision making : an international journal of the Society for Medical Decision Making.
[4] John Brazier,et al. Development of the Scharr HUD (Health Utilities Database) , 2013 .
[5] R. R. Holman,et al. UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82 , 2013, Diabetologia.
[6] John Hornberger. Computer modeling of diabetes and its complications: a report on the fifth mount hood challenge meeting. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[7] A J Palmer,et al. The Mt. Hood challenge: cross-testing two diabetes simulation models. , 2000, Diabetes research and clinical practice.
[8] Joshua T. Cohen,et al. 30 Years of Pharmaceutical Cost-Utility Analyses , 2012, PharmacoEconomics.
[9] Helen Dakin,et al. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database , 2013, Health and Quality of Life Outcomes.
[10] Alan Brennan,et al. Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge , 2018, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[11] Christopher James Sampson,et al. Model Registration: A Call to Action , 2017, PharmacoEconomics - Open.
[12] Joshua T. Cohen,et al. Can Economic Model Transparency Improve Provider Interpretation of Cost-Effectiveness Analysis? A Response. , 2017, Medical care.
[13] Ben Goldacre. The WHO joint statement from funders on trials transparency , 2017, British Medical Journal.
[14] Dr David M. Eddy. Accuracy versus Transparency in Pharmacoeconomic Modelling , 2012, PharmacoEconomics.
[15] Kay Dickersin,et al. The evolution of trial registries and their use to assess the clinical trial enterprise. , 2012, JAMA.
[16] P. Easterbrook,et al. Publication bias in clinical research , 1991, The Lancet.
[17] Mick Watson. When will ‘open science’ become simply ‘science’? , 2015, Genome Biology.
[18] Julia Earnshaw,et al. NICE Guide to the Methods of Technology Appraisal , 2012, PharmacoEconomics.
[19] J. Caro,et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[20] M J Buxton,et al. Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.
[21] Sean Ekins,et al. Ahead of Our Time: Collaboration in Modeling Then and Now , 2017, PharmacoEconomics.
[22] S. Goodacre,et al. Being economical with the truth: how to make your idea appear cost effective , 2002, Emergency medicine journal : EMJ.
[23] John P. A. Ioannidis,et al. Why Most Clinical Research Is Not Useful , 2016, PLoS medicine.
[24] P. Vemer,et al. AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users , 2015, PharmacoEconomics.
[25] David M Eddy,et al. Accuracy versus transparency in pharmacoeconomic modelling: finding the right balance. , 2006, PharmacoEconomics.
[26] Fiona Godlee,et al. All trials must be registered and the results published , 2013, BMJ.
[27] Dyfrig A Hughes,et al. Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[28] Maiwenn J Al,et al. Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force. , 2013, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[29] Reiner Leidl,et al. External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. , 2017, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[30] Nicholas C. Ide,et al. Trial Registration at ClinicalTrials.gov between May and October 2005. , 2005, The New England journal of medicine.
[31] David Moher,et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement , 2013, International Journal of Technology Assessment in Health Care.
[32] John Hornberger,et al. Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.
[33] Iris Lansdorp-Vogelaar,et al. A Systematic Comparison of Microsimulation Models of Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.
[34] Yaling Yang,et al. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement , 2018, Health and Quality of Life Outcomes.
[35] Alan Brennan,et al. Computer Modeling of Diabetes and Its Complications , 2007, Diabetes Care.
[36] Sean Ekins,et al. Time for Cooperation in Health Economics among the Modelling Community , 2012, PharmacoEconomics.
[37] Philip M Clarke,et al. Development of life-expectancy tables for people with type 2 diabetes. , 2009, European heart journal.